TY - JOUR
T1 - Targeted Therapy and Imaging Findings
AU - Shroff, Girish S.
AU - Benveniste, Marcelo F.
AU - De Groot, Patricia M.
AU - Wu, Carol C.
AU - Viswanathan, Chitra
AU - Papadimitrakopoulou, Vassiliki A.
AU - Truong, Mylene T.
N1 - Publisher Copyright:
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2017
Y1 - 2017
N2 - Non-small cell lung cancer (NSCLC) is usually diagnosed when it is not amenable to curative surgery or radiation. Many of these patients are candidates for systemic therapy. Median survival is only approximately 10 months, and, accordingly, treatment in advanced NSCLC is evolving toward a more personalized approach with the identification of genetic abnormalities based on biomarkers. For example, gene mutations in EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase) lead to a cascade of pathways resulting in uncontrolled growth, proliferation, and survival of tumor cells. Targeted therapies are aimed at the products of these mutated genes and include agents such as erlotinib and gefitinib (in EGFR-mutant NSCLC) or crizotinib (in ALK-positive NSCLC). Antiangiogenesis agents such as bevacizumab are another category of targeted therapy that inhibits vascular endothelial growth factors. The imaging characteristics of advanced NSCLC with genetic abnormalities, the evolution of targeted therapies and their imaging manifestations will be discussed.
AB - Non-small cell lung cancer (NSCLC) is usually diagnosed when it is not amenable to curative surgery or radiation. Many of these patients are candidates for systemic therapy. Median survival is only approximately 10 months, and, accordingly, treatment in advanced NSCLC is evolving toward a more personalized approach with the identification of genetic abnormalities based on biomarkers. For example, gene mutations in EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase) lead to a cascade of pathways resulting in uncontrolled growth, proliferation, and survival of tumor cells. Targeted therapies are aimed at the products of these mutated genes and include agents such as erlotinib and gefitinib (in EGFR-mutant NSCLC) or crizotinib (in ALK-positive NSCLC). Antiangiogenesis agents such as bevacizumab are another category of targeted therapy that inhibits vascular endothelial growth factors. The imaging characteristics of advanced NSCLC with genetic abnormalities, the evolution of targeted therapies and their imaging manifestations will be discussed.
KW - Kirsten rat sarcoma virus
KW - anaplastic lymphoma kinase
KW - epidermal growth factor receptor
KW - non-small cell lung cancer
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85030865234&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030865234&partnerID=8YFLogxK
U2 - 10.1097/RTI.0000000000000294
DO - 10.1097/RTI.0000000000000294
M3 - Article
C2 - 28832416
AN - SCOPUS:85030865234
SN - 0883-5993
VL - 32
SP - 313
EP - 322
JO - Journal of Thoracic Imaging
JF - Journal of Thoracic Imaging
IS - 5
ER -